What's Happening?
Forge Nano, a U.S.-based semiconductor equipment and advanced materials company specializing in Atomic Layer Deposition (ALD) technology, has announced a Joint Development Agreement (JDA) with Nanexa AB. This collaboration aims to develop scalable pharmaceutical
manufacturing capabilities for Nanexa's PharmaShell® drug delivery platform, which utilizes precisely engineered nanoscale coatings via ALD technology to enable long-acting injectable formulations. The agreement focuses on creating large-scale GMP-compliant ALD manufacturing equipment to support clinical development and future commercial production of Nanexa's proprietary and partnered programs. Nanexa's PharmaShell® platform is designed to apply to a wide range of active pharmaceutical ingredients, including small molecules and biologics, across various therapeutic areas. The partnership leverages Forge Nano's expertise in industrial ALD process development and equipment engineering, combined with Nanexa's knowledge in drug delivery and pharmaceutical development. This builds upon an existing relationship between the two companies, aiming to increase manufacturing capacity as Nanexa's programs advance.
Why It's Important?
This collaboration is significant for the U.S. pharmaceutical and advanced manufacturing sectors. By developing scalable ALD manufacturing capabilities for long-acting injectable medicines, it addresses a critical need for efficient and precise drug delivery systems. Long-acting injectables can improve patient adherence, reduce dosing frequency, and potentially enhance therapeutic outcomes, which has broad implications for chronic disease management and patient quality of life. For Forge Nano, this agreement expands the application of its ALD technology beyond semiconductors and defense batteries into the high-growth pharmaceutical market, diversifying its revenue streams and demonstrating the versatility of its core technology. For Nanexa, securing scalable manufacturing is crucial for bringing its PharmaShell®-enabled products, such as the GLP-1 program NEX-22, to market. This partnership could accelerate the development and commercialization of innovative drug formulations, potentially leading to new treatment options and a competitive advantage in the global pharmaceutical landscape. The focus on GMP-compliant manufacturing also underscores a commitment to quality and regulatory standards, which is vital for patient safety and market acceptance.
What's Next?
The immediate next step for Forge Nano and Nanexa will be to collaborate on the development of large-scale GMP-compliant ALD manufacturing equipment. This infrastructure and process know-how are intended to support Nanexa's PharmaShell® portfolio through clinical development and towards potential future commercial-scale production. The agreement is designed to create a clear pathway for increased manufacturing capacity as Nanexa's proprietary and partnered PharmaShell® programs progress. This includes Nanexa's internal product portfolio, its license agreement with Moderna, and other undisclosed collaborations with pharmaceutical companies. Future commercialization of PharmaShell®-enabled products will depend on successful development, regulatory approvals, and other market factors. The companies will likely focus on optimizing the ALD manufacturing process for various active pharmaceutical ingredients and ensuring compliance with stringent pharmaceutical industry standards to facilitate the advancement of these innovative drug delivery systems.
Beyond the Headlines
Beyond the immediate goal of scalable manufacturing, this partnership highlights a broader trend of cross-industry innovation, where advanced technologies from one sector, like ALD from semiconductors, are being adapted to solve complex challenges in another, such as pharmaceuticals. This interdisciplinary approach can unlock new possibilities for drug development and delivery, potentially leading to more effective and patient-friendly treatments. The precise nanoscale coatings offered by ALD could enable novel drug release profiles, targeted delivery, and enhanced drug stability, pushing the boundaries of what is currently possible in pharmacotherapy. Furthermore, the emphasis on 'long-acting' formulations could have significant societal impacts by improving medication adherence, particularly for chronic conditions, thereby reducing healthcare costs and improving public health outcomes. This collaboration also underscores the growing importance of advanced materials science and engineering in addressing critical needs across diverse industries, fostering a more integrated and technologically driven approach to innovation.
